Abstract Body

Background: An analysis of 4 ACTG studies, including 5332 subjects, identified an increase in the hazard of suicidality in efavirenz containing regimens compared to regimens containing atazanavir, atazanavir/ritonavir, lopinavir/ritonavir and zidovudine/lamivudine/abacavir. Rare but serious psychiatric adverse events (AEs), including suicide, have been included in postmarketing reports with efavirenz. We conducted a Multi-Item Gamma Poisson Shrinker (MGPS) disproportionality analysis based on data in the FDA Adverse Event Reporting System (AERS) database to assess the potential association of selected antiretrovirals (ARVs), including efavirenz, with suicidality. AERS primarily includes spontaneous serious AE reports from consumers and healthcare professionals of varying quality with fewer entries from clinical trials. Methodology: The AERS database (Q3 2012) search included MedDRA preferred terms “completed suicide”, “suicidal ideation”, and “suicide attempt”. In addition to the ARVs, fluoxetine and sertraline, antidepressants with a Black-Box Warning for suicidality, were included as positive controls. The MGPS method can provide a robust estimate of disproportionality measure (reporting above expected frequency) referred to as the EBGM (Empirical Bayesian Geometric Mean), and the corresponding 90% confidence interval (EB05, EB95). The threshold for a potential drug-event signal is generally considered to be EB05 ≥2. Results: The database included 29,836 AE reports among patients receiving efavirenz, atazanavir, darunavir, etravirine, nevirapine, and raltegravir, including 437 reports of completed suicide, suicidal ideation, and suicide attempt. Efavirenz and all comparator ARVs did not exceed the threshold for identification of a disproportional signal for suicide, suicidal ideation, and suicide attempt (EB05 Scores ≥2; Table). Fluoxetine and sertraline had EB05 Scores ≥2 for suicide, suicidal ideation, and suicide attempt. Conclusions: This analysis does not show a disproportional signal for suicide, suicidal ideation, and suicide attempt for efavirenz, atazanavir, darunavir, etravirine, nevirapine, and raltegravir. There are limitations to the AERS data, including a lack of certainty that reported adverse events are related to the drug, lack of sufficient detail in the reports, and underreporting of adverse events. Appropriate baseline psychiatric screening and counseling is important when starting patients on any ARV.